c-Rel-dependent monocytes are potent immune suppressor cells in cancer.
Rel/NF-kB
c-Rel-dependent monocytes
myelopoiesis
tumor immunotherapy
tumor microenvironment
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
25
04
2022
received:
02
11
2021
pubmed:
14
6
2022
medline:
4
10
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of leukocytes that are important for tumorigenesis and tumor immunotherapy. They comprise up to 10% of leukocytes in the blood of tumor patients and their depletion may be required for successful tumor immunotherapy. However, the identity of MDSCs remains obscure, primarily due to their heterogeneity and lack of a known lineage-specific transcription factor specifying their differentiation. Using single-cell transcriptomics and gene knockout approaches, we now describe a subset of murine and human myeloid suppressor cells, named rel-dependent monocytes (rMos), which are programmed by the transcription factor c-Rel of the NF-κB family. Unlike MDSCs described previously, the c-Rel-dependent monocytes expressed a high amount of the proinflammatory cytokine IL-1β together with a low level of suppressive molecule arginase 1. Both in vitro and in tumor-bearing mice, these c-Rel
Identifiants
pubmed: 35694784
doi: 10.1002/JLB.1MA0422-518RR
pmc: PMC9530019
mid: NIHMS1832674
doi:
Substances chimiques
Cytokines
0
NF-kappa B
0
Transcription Factors
0
Arginase
EC 3.5.3.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
845-859Subventions
Organisme : NIAID NIH HHS
ID : R01 AI136945
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143676
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152195
Pays : United States
Informations de copyright
©2022 Society for Leukocyte Biology.
Références
Immunity. 2010 Jun 25;32(6):790-802
pubmed: 20605485
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31662347
Immunobiology. 2011 Nov;216(11):1192-202
pubmed: 21803441
Blood. 2004 Oct 15;104(8):2224-34
pubmed: 15231578
Immunity. 2009 Dec 18;31(6):932-40
pubmed: 20064450
Int J Mol Med. 2007 Jul;20(1):129-36
pubmed: 17549399
Gut. 2009 Aug;58(8):1078-83
pubmed: 19240061
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Science. 2010 May 7;328(5979):749-52
pubmed: 20339029
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Sci Immunol. 2020 Feb 21;5(44):
pubmed: 32086381
Nat Immunol. 2006 Mar;7(3):311-7
pubmed: 16462739
Front Immunol. 2021 Jan 14;11:619253
pubmed: 33519825
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415
pubmed: 31152140
J Immunol. 2018 Jan 15;200(2):422-431
pubmed: 29311384
Oncoimmunology. 2016 Jun 27;5(7):e1196312
pubmed: 27622051
Blood. 2008 Apr 15;111(8):4233-44
pubmed: 18272812
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
pubmed: 21081700
Lung Cancer. 2013 Sep;81(3):468-474
pubmed: 23850196
Cell Immunol. 2018 Aug;330:188-201
pubmed: 29482836
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32907925
Breast Cancer Res Treat. 2010 Aug;123(1):39-49
pubmed: 19898981
Nat Methods. 2017 Oct;14(10):979-982
pubmed: 28825705
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Science. 2012 Nov 16;338(6109):891-2
pubmed: 23161983
Cancer Res. 2018 Jan 1;78(1):157-167
pubmed: 29089297
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
J Immunol. 2002 Sep 15;169(6):3329-35
pubmed: 12218154
Oncoimmunology. 2017 Apr 20;6(6):e1316437
pubmed: 28680747
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
Eur J Immunol. 2010 Nov;40(11):2969-75
pubmed: 21061430
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Acta Neuropathol Commun. 2018 Mar 1;6(1):18
pubmed: 29490700
Genes Immun. 2016 Jul;17(5):305-12
pubmed: 27278126
Nat Cancer. 2020 May;1(5):507-517
pubmed: 33458695
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s
pubmed: 17255300
Nat Methods. 2020 Apr;17(4):405-413
pubmed: 32123397
Cell Mol Immunol. 2021 Apr;18(4):829-841
pubmed: 33077904
Immunol Rev. 2018 Jan;281(1):57-61
pubmed: 29247996
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Nat Genet. 2010 Dec;42(12):1126-1130
pubmed: 21037568
Nature. 2019 Feb;566(7745):496-502
pubmed: 30787437
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
J Clin Cell Immunol. 2015 Apr;6(2):
pubmed: 26317041
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Immunother Cancer. 2017 Dec 19;5(1):101
pubmed: 29254508
Cell Stress. 2019 Jul 01;3(9):284-294
pubmed: 31535085
J Invest Dermatol. 2002 Jun;118(6):915-22
pubmed: 12060384
EMBO J. 2002 Mar 15;21(6):1379-88
pubmed: 11889043
Vaccines (Basel). 2016 Sep 09;4(3):
pubmed: 27618112